Posterior Uveitis - Pipeline Review, H2 2016 - Product Image

Posterior Uveitis - Pipeline Review, H2 2016

  • ID: 3960445
  • Report
  • 65 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aciont Inc.
  • Neuroptis Biotech
  • Oculis ehf
  • pSivida Corp.
  • Sandoz International GmbH
  • MORE
Posterior Uveitis - Pipeline Review, H2 2016

Posterior Uveitis - Pipeline Review, H2 2016, provides an overview of the Posterior Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. One of the types of uveitis is posterior uveitis. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights:

Posterior Uveitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Posterior Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Posterior Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Posterior Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 2, 2 and 3 respectively.Posterior Uveitis.

Posterior Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Posterior Uveitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Posterior Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Posterior Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Posterior Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Posterior Uveitis (Ophthalmology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Posterior Uveitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Posterior Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aciont Inc.
  • Neuroptis Biotech
  • Oculis ehf
  • pSivida Corp.
  • Sandoz International GmbH
  • MORE
Introduction

Posterior Uveitis Overview

Therapeutics Development

Pipeline Products for Posterior Uveitis - Overview

Posterior Uveitis - Therapeutics under Development by Companies

Posterior Uveitis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Posterior Uveitis - Products under Development by Companies

Posterior Uveitis - Companies Involved in Therapeutics Development

Aciont Inc.

Neuroptis Biotech

Oculis ehf

pSivida Corp.

Regeneron Pharmaceuticals Inc

Sandoz International GmbH

Santen Pharmaceutical Co., Ltd.

Posterior Uveitis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone sodium phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EYS-606 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluocinolone acetonide SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sarilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sirolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Posterior Uveitis - Dormant Projects

Posterior Uveitis - Discontinued Products

Posterior Uveitis - Product Development Milestones

Featured News & Press Releases

Oct 04, 2016: Phase 3 trial of Medidur in Posterior Segment Uveitis Meets Enrollment Target

Aug 15, 2016: Topline Results from First Phase 3 Trial of pSividas Medidur Presented at ASRS Annual Meeting

Aug 09, 2016: Primary Endpoint Met in pSivida's Utilization Study of New Medidur Inserter with Smaller Diameter Needle

Jul 27, 2016: pSivida's Medidur Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001)

Jul 14, 2016: Investigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve

May 02, 2016: pSividas Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe

Mar 15, 2016: Additional Favorable Six-Month Safety Results for pSividas Medidur for Posterior Uveitis

Dec 28, 2015: pSivida Plans Medidur EU Marketing Approval Application Based on Single Phase 3 Clinical Trial

Dec 22, 2015: pSivida Medidur Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis

Sep 28, 2015: pSivida Announces NDA for Medidur Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs

May 19, 2015: pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur for Posterior Uveitis

Mar 26, 2015: pSivida Completes Targeted Enrollment of Phase III Trial of Medidur for Posterior Uveitis

Apr 15, 2013: Aciont To Present at ARVO 2013 Annual Meeting

List of Tables

Number of Products under Development for Posterior Uveitis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Posterior Uveitis - Pipeline by Aciont Inc., H2 2016

Posterior Uveitis - Pipeline by Neuroptis Biotech, H2 2016

Posterior Uveitis - Pipeline by Oculis ehf, H2 2016

Posterior Uveitis - Pipeline by pSivida Corp., H2 2016

Posterior Uveitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016

Posterior Uveitis - Pipeline by Sandoz International GmbH, H2 2016

Posterior Uveitis - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Posterior Uveitis - Dormant Projects, H2 2016

Posterior Uveitis - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Posterior Uveitis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Aciont Inc.
- Neuroptis Biotech
- Oculis ehf
- pSivida Corp.
- Regeneron Pharmaceuticals Inc
- Sandoz International GmbH
- Santen Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll